Eli Lilly says study of Cialis co-administered with Finasteride meets endpoint

theflyonthewall.com

Eli Lilly and Company (LLY) presented results today at the annual European Association of Urology Congress in Milan, Italy, of a study that showed Cialis 5 mg once daily co-administered with finasteride significantly improved scores on the International Prostate Symptom Score, compared to placebo/finasteride, in men with lower urinary tract symptoms of benign prostatic hyperplasia and enlarged prostates. On a pre-specified secondary measure, Cialis/finasteride also improved erectile function scores versus placebo/finasteride in those men who had both LUTS/BPH and erectile dysfunction at baseline. This is the first study to report co-administration of Cialis and finasteride in men with LUTS/BPH. Cialis is a phosphodiesterase type 5 inhibitor approved by the FDA for the signs and symptoms of BPH and both ED and the signs and symptoms of BPH (ED+BPH). Finasteride is a type II 5alpha-reductase inhibitor approved by the FDA for the treatment of BPH in men with an enlarged prostate.

Rates

View Comments (0)